Drug Discovery World
FEBRUARY 20, 2024
The contract was awarded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program, through the Medical Chemical, Biological, Radiological, and Nuclear (CBRN) Defense Consortium (MCDC) requirement 22-05, ‘Adjuvant Activity to Vaccines Prototype’.
The Pharma Data
DECEMBER 23, 2020
All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. It will be funded by the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 29, 2022
Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein16 and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. W911QY-21-9-0001.
The Pharma Data
MARCH 25, 2022
Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. W911QY-21-9-0001.
The Pharma Data
AUGUST 22, 2021
More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales. W911QY-21-9-0001. About AstraZeneca.
Expert insights. Personalized for you.
52 
Let's personalize your content